Despite much progress in the treatment of childhood leukemias, infants carrying MLL rearrangements have a very poor prognosis (Pui et al., 2011); thus, improving therapies for MLL-FP patients remains an unmet need. The gene discussed is KMT2A; the disease is leukemia.